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Background:Cytomegalovirus (CMV) is the leading infectious agent causing congenital sensorineural hearing loss
and psychomotor retardation. CMV vaccine is currently unavailable and treatment options in pregnancy are lim-
ited. Susceptible pregnant women caring for children are at high risk for primary infection. CMV educational and
hygienic measures have the potential to prevent primary maternal infection.
Methods: A mixed interventional and observational controlled study was conducted to investigate the effective-
ness of hygiene information among pregnantwomen at risk for primary CMV infection for personal/occupational
reasons. In the intervention arm, CMV-seronegative women, identiﬁed at the time of maternal serum screening
for fetal aneuploidy at 11–12 weeks of gestation, were given hygiene information and prospectively tested for
CMV until delivery. The comparison arm consisted of women enrolled at delivery who were neither tested for
nor informed about CMV during pregnancy, and who had a serum sample stored at the screening for fetal aneu-
ploidy. By design, groups were homogeneous for age, parity, education, and exposure to at least one risk factor.
The primary outcome was CMV seroconversion. Acceptance of hygiene recommendations was a secondary ob-
jective and was measured by a self-report.
Findings: Four out of 331 (1.2%) women seroconverted in the intervention group compared to 24/315 (7.6%) in
the comparison group (delta=6.4%; 95% CI 3.2–9.6; P b 0.001). Therewere 3 newbornswith congenital infection
in the intervention group and 8 in the comparison group (1 with cerebral ultrasound abnormalities at birth).
Ninety-three percent of women felt hygiene recommendations were worth suggesting to all pregnant women
at risk for infection.
Interpretation: This controlled study provides evidence that an intervention based on the identiﬁcation and hy-
giene counseling of CMV-seronegative pregnantwomen signiﬁcantly preventsmaternal infection.While waiting
for CMV vaccine to become available, the intervention describedmay represent a responsible and acceptable pri-
mary prevention strategy to reduce congenital CMV.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cytomegalovirus (CMV) is the most common intrauterine infection.
The burden caused by congenital CMV disease reportedly exceeds that
caused by other childhood diseases such as Down syndrome, fetalaboratories, Fondazione IRCCS
cation (CCPE) Study Group are
. This is an open access article underalcohol syndrome and spina biﬁda (Cannon and Davis, 2005). Mental
retardation, motor disabilities and hearing loss are among the most
severe sequelae of congenital CMV infection (McCracken et al., 1969;
Reynolds et al., 1974; Hanshaw et al., 1976). CMV has been assigned
the highest priority for vaccine development (Arvin et al., 2004), but
presently there is no licensed CMV vaccine.
Studies have identiﬁed two sources of maternal CMV infection:
sexual activity and contact with young children (Fowler and Pass,
2006). However, the latter is considered the most important one as
the high circulation rate of CMV in infants and children of pre-school
age puts seronegative pregnant women caring for young children at
high risk for CMV infection (Stagno et al., 1984; Taber et al., 1985;the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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rect contact with infectious bodily ﬂuids such as saliva and urine
(Cannon et al., 2011). Molecular epidemiology studies have demon-
strated horizontal transmission among children and from child to
mother (Adler, 1986; Revello et al., 2008).
In the past, 2 small studies performed by the same group in the
USA and one French study suggested that behavioral interventions
and avoiding intimate contacts with young children could reduce
CMV seroconversion in pregnant women (Adler et al., 1996, 2004;
Vauloup-Fellous et al., 2009). However, each of these studies had im-
portant limitations in their design and/or implementation and the
true effectiveness and/or actual feasibility of hygiene recommenda-
tions in terms of routine use in general practice could not be
assessed.
Here a controlled trial was conducted to assess the effectiveness of
an intervention aimed at identifying and educating CMV-seronegative
pregnant women with hygiene measures for primary CMV prevention.
The target population consisted of pregnant womenwith frequent con-
tacts with young children and, thus, at high risk for primary CMV
infection.
2. Methods
2.1. Design of the Study
The study included a prospective intervention group and an obser-
vational comparison group (Fig. 1). Details regarding the identiﬁcation
of women at risk for CMV infection together with eligibility criteria
are reported in the Suppl. data. Brieﬂy, in the intervention group, all
consecutive pregnant women undergoing serum screening for fetal an-
euploidy at 11–12 weeks of gestation during the study period were
assessed for risk factors for CMV infection. Women were considered at
risk if they had their own child or had frequent contacts with children
other than their own of less than 36 months of age. Pregnant women
working with children of the same age group either full time or part
time (health care or child care providers) together with pregnant
women of less than 20 years of age were also considered at risk.
Women, who were either CMV-seronegative or not previously testedFig. 1. Overview of the study design. Participation in the study was restricted to adult (N18 y
11–12 weeks of gestation and at risk for CMV infection. Interpretation of IgM-positive results an
version or primary infection in the ﬁrst trimester of gestationwere performed outside of the pre
(dotted boxes).for CMV immune status, were invited to participate in the study. Sus-
ceptible women received information about CMV and preventive mea-
sures, and were prospectively monitored for CMV antibody at 18weeks
of gestation and at delivery. In case of primary CMV infection diagnosed
either at enrollment or at 18 weeks of gestation, the option of prenatal
diagnosis was discussed and pregnancy managed accordingly. In the
absence of maternal infection, women received standard prenatal
care according to Italian guidelines (www.snlg-iss.it/lgn_gravidanza_
ﬁsiologica_agg_2011).
Pregnant women in the comparison group were consecutively
assessed for risk factors at pre-delivery visit at 36–37weeks of gestation
or at admission for delivery. Women at risk for CMV infection who had
not been tested before and were unaware of CMV, were invited to par-
ticipate in the study provided they had undergone fetal aneuploidy
screening. Samples stored at 11–12 weeks of gestation were retrospec-
tively tested for CMV antibody and CMV IgG-negative women were re-
tested at delivery.
Enrollment of the intervention and comparison group took place
during the same period of time. Pregnant women of the intervention
group were enrolled at both sites (Pavia and Turin), whereas pregnant
women of the comparison group were enrolled at the Turin center
only. By design, study groups were homogeneous for age, parity, educa-
tion and exposure to at least one risk factor for CMV infection. All new-
borns born to women with primary infection or seroconversion were
examined for congenital infection.
Additional information about the study background and design,
and enrollment are available (Suppl. data). The protocol of
the study (in Italian) is available at the following website http://
www.cittadellasalute.to.it/index.php?option=com_content&view=
article&id=1809%3Aprogetti-regina-margherita-santanna&catid=
138&Itemid=534, and also uploaded as an online component to this
article.
The study was approved by the Ethics Committee of the two partic-
ipating Italian centers, i.e., Department of Obstetrics and Gynecology,
Fondazione IRCCS Policlinico San Matteo, Pavia (no. 20120040139)
andDepartment of Obstetrics andGynecology, Ospedale S. Anna, Torino
(no. 474 61399/AZ.10). Pregnant women gave written informed con-
sent to be included in the study before participation.ears of age) Italian pregnant women undergoing serum screening for fetal aneuploidy at
d prenatal or neonatal diagnosis of congenital CMV infection in case of maternal serocon-
sent study as part of routine care in case of suspected or conﬁrmed primary CMV infection
1207M.G. Revello et al. / EBioMedicine 2 (2015) 1205–12102.2. Objectives of the Study and Outcome Measures
The primary objective of the study was to investigate the effective-
ness of CMV information and hygiene recommendations for prevention
of CMV infection in seronegative pregnantwomen at risk for primary in-
fection. The outcomemeasure was seroconversion, i.e., de novo appear-
ance of CMV-speciﬁc IgG in a previously seronegative woman. The
secondary end point was to assess acceptance of and adherence to hy-
giene recommendations, and was measured with a self-report.2.3. Pre-Study Activities
To develop a common communication algorithm and optimize CMV
information and hygiene counseling, midwives and physicians of the
two participating centers involved in the study underwent a short, ded-
icated course on basic techniques of conscious communication, active
listening and motivational communication (Istituto Change, Torino).Table 1
Baseline characteristics.
Variable Intervention
(n = 331)
Comparison
(n = 315)
P2.4. Intervention
Women were offered basic information about this study and CMV
antibody testing. Consenting CMV-seronegative women received an in-
formation session (15–20 min) illustrating the nature of the virus, the
potential consequences to the fetus, routes of transmission and ways
of preventing the infection. Speciﬁcally, participantswere invited to fre-
quently wash their hands after exposure to young children's bodily
ﬂuids as well as surfaces touched by children (toys, high chair, stroller,
etc.). Women were also invited to avoid kissing children on the
mouth/cheeks and not to share utensils, food, drinks, washcloths etc.
Use of gloves and avoidance of sleeping in the same bed were not
suggested.
The above information was also provided in writing. In addition, a
pictorial card showing protective and risky behaviors (Fig. 1 Suppl.
data) was given to each woman with the recommendation to keep it
in sight at home. Participants were free to ask questions during the
session and afterwards. A short (about 5 min) additional session to
reinforce hygiene recommendations was scheduled at follow-up visit
at 18 weeks of gestation. Women were also invited to ﬁll in a short
questionnaire (Suppl. data) every 6 weeks starting at 18 weeks of
gestation.
Women enrolled in the comparison group who were found to be
CMV-seronegative at deliverywere informed of the potential risks asso-
ciatedwith CMV susceptibility in future pregnancies. Theywere advised
to have their serostatus promptly checked in case of a new pregnancy
and, if still seronegative, to follow the hygiene recommendations. Sus-
ceptible women also received written information and the pictorial
card.Age (years) 33 (30–36) 34 (32–37) b0.01
Parity
Pluriparous 266 (80) 270 (86) 0.07
Risk factors
Contact with children b 36 months
Own child 251 (76) 261 (83) 0.02
Familiar or other childrena 88 (27) 53 (17) b0.01
Occupationb 33 (10) 12 (4) b0.01
Age b 20 yrs 2 (1) 0 0.49
Education 0.59
Primary 25 (8) 21 (7)
Secondary 130 (39) 134 (42)
Tertiary 176 (53) 160 (51)
Duration of the study (days)c 194 (186–200) 194 (188–201) 0.30
Data are median (interquartile range) or n (%).
a Family members other than own child or other children but outside of a child-related
professional activity.
b Health professionals or child care providers.
c Duration of the study was calculated by subtracting the time of gestation (in days) at
fetal aneuploidy test from the time of gestation at delivery or last control.2.5. Laboratory Tests
Levels of virus-speciﬁc IgG and IgM were determined using Liaison
CMV IgG II and CMV IgM II (DiaSorin), and Vidas CMV IgG and IgM
(BioMérieux). IgG avidity was determined with BEIA CMV IgG Avidity
(Techno Genetics). Viral DNA in amniotic ﬂuid or urinewas determined
by real-time polymerase chain reaction (PCR) assay (CMV ELITe MGB
Kit, ELITechGroup). Seroconversion was based on appearance of CMV-
speciﬁc IgG in a previously seronegative woman. Diagnosis of primary
CMV infection was based on detection of CMV-speciﬁc IgM and a low/
intermediate IgG avidity index. An avidity index b25% indicated a
primary infection acquired since less than 3months. Congenital CMV in-
fectionwas diagnosed antenatally by detection of CMVDNA in amniotic
ﬂuid and postnatally by detection of viral DNA in urine samples collect-
ed within the ﬁrst two weeks of life.2.6. Statistical Analysis
We estimated that 308 seronegative women were needed in each
group for the study to show a reduction in seroconversion rate from
5% to 0.5% with 80% power (alpha, two-sided = 1%). Data were de-
scribed asmedian and range if continuous and as counts and percentage
if categorical. Risk factors at baseline were compared between groups
using the Chi-square or theWilcoxon testwhere appropriated. The inci-
dence of seroconversion and exact binomial 95% conﬁdence interval
was estimated for each group, and compared with the Fisher exact
test. The risk difference, the number needed to treat/counsel, and the
odds ratio (OR) with a 95% CI were computed by Stata 13.1 (StataCorp,
College Station, TX, USA). Logistic regression model was used to esti-
mate the effect of not receiving counseling on seroconversion, while
adjusting for confounders. Age (continuous), parity (pluriparous), edu-
cation (secondary and tertiary vs primary) and risk factors (to have
their own child or frequent contacts with children b 36 months, to
have an occupational risk) were used as covariates. A two-sided P
value of less than 0.05 was considered statistically signiﬁcant.
2.7. Role of the Funding Source
The funding source had no role in the study design, data collection,
data analyses, or data interpretation. The corresponding author had
full access to all the data in the study and had ﬁnal responsibility for
the decision to submit for publication.
3. Results
3.1. Enrollment and Outcomes
Enrollment took place between January 2013 and April 2014. The
last woman enrolled in the intervention group completed the study in
November 2014. Baseline characteristics of the two study groups are re-
ported in Table 1. Median age was close in the 2 groups (33 vs 34 years,
in intervention and comparison group, respectively), despite a statisti-
cally signiﬁcant difference, and thus was not further considered as a
confounder. Conversely, the distribution of risk factors was different in
the 2 groups and their confounding effect was adjusted for in themulti-
variable logistic model.
In the intervention arm, 4096 consecutive Italian pregnant women
undergoing genetic screeningwere assessed for eligibility (Fig. 2). Over-
all, 745 were enrolled and tested for CMV antibody. Of these, 381 (51%)
Fig. 2. Enrollment and outcome. Interventio group. Twenty-one women found to be CMV IgM-positive at enrollment were further tested for IgG avidity (dotted box). Avidity index was
high (N45%), thus excluding a primary CMV infection, in the previous 3months in 15women. Onewoman had avidity in the intermediate range (25%–45%), indicating a possible primary
infection in thepast 6months, and5womenhad low (b25%) avidity indexes compatiblewith a recent (b3months) primary infection. Twowomendiagnosedwith primary infection in the
ﬁrst trimester of gestation opted for prenatal diagnosis of congenital CMV infection and amniocentesis was performed at 20 weeks of gestation.
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mation and hygiene counseling. During the study, 13 women had a
spontaneous abortion between 12 and 18 weeks of gestation. Four of
these women were not further tested, whereas 9 were still CMV-
seronegative about one year after completion of the study. In addition,
37 (23 + 14) women were lost to follow-up. Two women
seroconverted between 12 and 18 weeks of gestation and 2 between
18 weeks and delivery. Overall, 4 of the 331 women who completed
the study seroconverted (1.2%; 95% CI 0.3–3.1). Detailed informationFig. 3.Enrollment and outcome. Comparison group. In the comparison group, 56womenwere e
hygiene information andweremonitored for CMV during pregnancy. Fourteenwomenwho tes
avidity of CMV-speciﬁc IgG (dotted box). A low avidity index indicating a primary infection a
seroconverted during pregnancy, 4 were IgM-negative when tested at delivery. All the 291 CMabout these 4 women is reported in Table 1 (Suppl. data). In 5
women, CMV-speciﬁc IgM and IgG of low avidity indicating a primary
CMV infection acquired in the ﬁrst trimester of gestation were detected
when they were ﬁrst tested at 11–12 weeks of gestation (Fig. 2).
In the comparison arm, of the 4732 women assessed for eligibility at
36–37 weeks of gestation or at delivery, 533 were enrolled (Fig. 3). Of
these women, 315 (59%) were found to be CMV-seronegative on
serum samples stored at 11–12 weeks of gestation. When retested
around or at delivery, it was found that 24 women had seroconvertedxcludedbecause theywere CMV-seronegative at the beginning of pregnancy, they received
ted IgM-positive on stored serum samples at 11–12weeks of gestationwere also tested for
cquired in the ﬁrst trimester of gestation was found in 4 of them. Of the 24 women who
V-seronegative women at delivery received CMV counseling.
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women are reported in Table 2 (Suppl. data). Four additional women
were retrospectively diagnosed with a primary CMV infection acquired
in the ﬁrst trimester of gestation on the basis of CMV-speciﬁc IgM and
IgG of low avidity (Fig. 3).
Overall, 9 women suffered from primary CMV infection during the
ﬁrst trimester of gestation and did not receive any information. When
theywere included, the incidence of primary CMV infection in pregnan-
cy among women not receiving information rose to 9%, i.e., 7.6% (24/
315) plus 1.4% [9/(9 + 315 + 331)]. The cumulative incidence of sero-
conversion in susceptible pregnantwomenwhodid not receive CMV in-
formation was calculated as the incidence of seroconversion in the
intervention and comparison group (during the ﬁrst 12 weeks of gesta-
tion) plus the incidence of seroconversion after 12weeks of gestation in
the comparison group.
3.2. Primary Objective
The seroconversion rate in the intervention (1.2%) was signiﬁcantly
lower than in the comparison (7.6%) group (Δ= 6.4%, 95% CI 3.2–9.6;
P b 0.001). The corresponding number needed to treat/counsel to pre-
vent one seroconversion was 16 (1/0.064) women (95% CI 10–30). Sus-
ceptible pregnant women who received CMV information had a lower
risk (1.2/7.6) of acquiring primary CMV infection than women who
were not informed (crude OR 0.15; 95% CI 0.05–0.43). The risk of infec-
tion was signiﬁcantly reduced also after adjustment for potential con-
founders (Adj OR 0.14; 95% CI 0.05–0.41).
3.3. Congenital Infection
Eleven of the 28 (39.3%) neonates (3 in the intervention and 8 in the
comparison group) born to seroconverted mothers were found to be
congenitally infected at birth (Fig. 2 Suppl. data). Ten infected infants
were asymptomatic at birth and have remained so during the follow-
up. One infected neonate born to a woman enrolled in the comparison
group had cerebral vasculitis diagnosed by an ultrasound scan at birth
and at 3 and 6 months of age. Presumed onset of maternal infection
was around 14–15 weeks of gestation. This infant did not receive CMV
therapy and appeared to be asymptomatic when last seen at 6 months
of age.
Of the 5women in the intervention groupwhowere diagnosedwith
a primary CMV infection acquired in the ﬁrst trimester of gestation, 2
women delivered uninfected babies and 3 opted for termination of the
pregnancy. Virologic outcome of pregnancies was unknown for 2 of
these women (including one carrying twins) who terminated pregnan-
cy at 12 weeks of gestation (products of conception were not exam-
ined), while fetal infection was diagnosed at amniocentesis in the
remainingwoman (Fig. 2 Suppl. data). None of the 4women in the com-
parison groupwhowere retrospectively diagnosedwith aﬁrst trimester
primary infection delivered a CMV-infected newborn (Fig. 2 Suppl.
data).
3.4. Secondary Objective
Overall, 932 questionnaires were returned and preliminary data in-
dicate that, when following the recommendations, lack of time was
the major problem, while knowledge of risks helped the most. In addi-
tion, 80% of respondents reported following the recommendations
often (66%) or always (14%) during pregnancy. Finally, 93% of re-
sponders estimated the recommendationsworth suggesting to all preg-
nant women at risk for infection.
4. Discussion
Our controlled study provides evidence that a primary prevention
strategy based on the identiﬁcation and provision of adequateinformation to susceptible pregnantwomen at risk for primary infection
are highly effective in reducing the rate of maternal primary CMV infec-
tion and, ultimately, congenital CMV infection. In the past 20 years only
a handful of primary studies have addressed the issue of prevention of
primary CMV infection by educational interventions (Harvey and
Dennis, 2008; Hamilton et al., 2014). Two small studies performed in
Virginia, USA, in the 1990s by SP Adler and colleagues, reported that fol-
lowing hygiene education, pregnantwomenwere signiﬁcantly less like-
ly to acquire CMV infection thanwere nonpregnantwomen (Adler et al.,
1996, 2004). In the only subsequent study investigating the role of hy-
giene counseling in a large population of French pregnant women test-
ed at 12weeks of gestation, a reduction in CMV infection from 0.035% to
0.008% per pregnant-woman week was reported by comparing the
number of seroconversions between 12 and 36weeks gestation (i.e., fol-
lowing hygiene counseling) with the number of primary infections ac-
quired between 0 and 12 weeks gestation (i.e., before counseling)
(Vauloup-Fellous et al., 2009). However, in the above studies, the edu-
cation interventions as well as study populations were quite different,
and minimal or no demographics were provided.
One crucial and challenging aspect of our studywas the identiﬁcation
of a suitable comparison group.We exploited the fact that themajority of
Italian pregnantwomen undergo serum screening for fetal aneuploidy at
11–12 weeks of gestation (European Ligand Assay Society, 2009), and
that on that occasion an aliquot of serum is routinely stored. On this
basis, women homogenous for age, parity, education and exposure to
risk factors could be enrolled in parallel in the prospective intervention
and in the observational comparison arm. Importantly, the duration of
the study in the two study groups was also the same (from 12 weeks
of gestation to delivery), thus eliminating a potentially important vari-
able such as difference in sexual activity during pregnancy (as in the
French study, Vauloup-Fellous et al., 2009) as well as between pregnant
and non-pregnant women (as in the US studies, Adler et al., 1996, 2004).
We devised a type of intervention that, if successful, could be further
tested in larger trials and, ultimately, translated into general practice.
We focused on pregnant women known to be at increased risk of infec-
tion, i.e., women caring for young children. These women were ﬁrst of-
fered CMV testing and, if seronegative, they were informed about CMV
and preventionmeasures to be adopted. Informationwas kept as simple
as possible. However, as hygiene recommendations implied substantial
and sustained behavioral changes, active involvement was encouraged
and a positive attitude in the woman was considered crucial for a suc-
cessful intervention (see Suppl. data). Unlike the two previous studies
performed in the USA (Adler et al., 1996, 2004), our intervention did
not include an educational video. In addition, use of gloves and recom-
mendation not to sleep in the same bed with the child was not sug-
gested. Finally, liquid soap and disposable gloves were not provided,
and home visitswere not performed. As a result, an 84% reduction in se-
roconversion rate was observed: a ﬁnding strickingly similar to what
previously reported by Adler et al. (2004) Reiteration of recommenda-
tions during antenatal classes may further improve the intervention ef-
fectiveness, as reported for toxoplasmosis (Breugelmans et al., 2004).
We do not know which of the suggested recommendations was most
effective in reducing the seroconversion rate in the intervention
group. No difference was previously reported, for a number of protec-
tive or risky behaviors, between infected and uninfected mothers of
children excreting CMV (Adler et al., 2004).
Adherence to suggested recommendations is still under examina-
tion. However, preliminary data indicate that 80% women reported
substantial or complete compliance with suggested recommenda-
tions. According to one study, mothers were able tomake and sustain
behavioral changes for more than 6months and were not necessarily
concerned about reducing intimate contact with their children
(Adler et al., 2004). Importantly, in our study, 93% of the women
felt that the recommendations are worth suggesting to all women
at risk for infection. This ﬁnding shows that an intervention like the
one herein reported would be highly acceptable to the target
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2012).
An additional ﬁnding of our study was that 9 primary maternal in-
fections occurred in the ﬁrst trimester of gestation, the highest risk pe-
riod in case of virus transmission to the fetus (Enders et al., 2011). Based
on results of our study, it is reasonable to hypothesize that some infec-
tions would have been avoided had these women been informed at an
earlier stage of pregnancy. Ideally, all women should be tested for
CMV antibody and informed before pregnancy. A further additional
by-product of our study is that hundreds ofwomen enrolled in the com-
parison group and found to be susceptible to CMV received post-partum
CMV information. Should thesewomenbecomepregnant again, it is less
likely they will be inadvertently exposed to CMV. Indeed, in a popula-
tion of women receiving fertility treatment, preconception screening
and counseling seemed to have the potential to reduce CMV exposure
in pregnancy (Reichman et al., 2014). Preconception testing would
also reduce problems arising from the detection and interpretation of
CMV-speciﬁc IgM antibody in an already pregnant woman (Revello
and Gerna, 2002; Guerra et al., 2007).
Finally, in view of the 15–20% rate of spontaneous abortion reported
in the general population in Italy (ISTAT, http://www.istat.it, 2014), it is
difﬁcult to hypothesize whether CMV had an etiological role in the
spontaneous abortion observed in the 4 women in the intervention
group (representing about 1% of CMV-seronegative women initially en-
rolled) who could not be further tested.
Hopefully, an effective CMV vaccine will eventually limit congenital
CMV (Grifﬁths et al., 2013) but this is not foreseen in the near future. In
the meantime, based on the uncertain efﬁcacy of the costly treatment
with hyperimmune globulin (Nigro et al., 2005; Revello et al., 2014), re-
ducing rates of primary infection in pregnancy by alternative prevention
strategies should be carefully considered.Contributors
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